Thrombopoietin is ineffective in a mouse model of motor neuron disease

about

One universal common endpoint in mouse models of amyotrophic lateral sclerosis.Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

P2860

Q33936763-E55AAA9A-8AF5-4575-8FE4-372227A50B43 Q33985590-3E35F462-3E08-40F3-9BBB-36B26B610B13

P2860

Thrombopoietin is ineffective in a mouse model of motor neuron disease

Item

http://www.wikidata.org/entity/Q58125301

description

article

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована в січні 2008

@uk

name

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@en

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@nl

type

Item

label

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@en

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@nl

prefLabel

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@en

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@nl

P1476

Thrombopoietin is ineffective in a mouse model of motor neuron disease

@en

P2093

Andrew Caraganis

http://www.w3.org/2001/XMLSchema#string

Susanna Benn

http://www.w3.org/2001/XMLSchema#string

P2860

Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation

Effect of interferon alpha and ribavirin treatment on serum levels of transforming growth factor-beta1, vascular endothelial growth factor, and basic fibroblast growth factor in patients with chronic hepatitis C

Neurotrophic factor therapy--prospects and problems.

Platelet-rich plasma: evidence to support its use.

Benefit of vitamin E, riluzole, and gabapentin in a transgenic model of familial amyotrophic lateral sclerosis.

Role of muscle insulin-like growth factors in nerve sprouting: suppression of terminal sprouting in paralyzed muscle by IGF-binding protein 4.

A clinical trial of creatine in ALS.

IGF-I deficient mice show reduced peripheral nerve conduction velocities and decreased axonal diameters and respond to exogenous IGF-I treatment.

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis.

Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS.

P304

354-358

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/17482960802103040

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Robert H Brown

Merit E Cudkowicz

P577

2008-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18608089

http://www.w3.org/2001/XMLSchema#string

Thrombopoietin is ineffective in a mouse model of motor neuron disease

about

P2860

P2860

Thrombopoietin is ineffective in a mouse model of motor neuron disease

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698